title: Leptin counteracts sodium butyrate-induced apoptosis in human colon cancer HT-29 cells via NF-kappaB signaling.
abstract: This study shows that leptin induced a rapid phosphorylation of p42/44 mitogen-activated protein kinase, an enhancement of both NF-kappaB DNA binding and transcriptional activities, and a concentration-dependent increase of HT-29 cell proliferation. These effects are consistent with the presence of leptin receptors on cell membranes. The leptin induction of cell growth was associated with an increase of cell population in S and G2/M phase compared with control cells found in G0/G1 phase of the cell cycle. Moreover, cyclin D1 immunoreactivity was enhanced in leptin-treated HT-29 cells and this increase was essentially associated with cell population in G0/G1 phase. On the other hand, we observed that sodium butyrate inhibited cell proliferation by blocking HT-29 cells in G0/G1 phase of the cell cycle. Interestingly, at physiological concentration, leptin prevented sodium butyrate-induced morphological nucleus changes, DNA laddering and suppressed butyrate-induced cell cycle arrest. This anti-apoptotic effect of leptin was associated with HT-29 cell proliferation and activation NF-kappaB pathways. However, the phosphorylation of p42/44 MAP kinase in response to leptin was reduced in butyrate-treated cells. These data demonstrated that leptin is a potent mitogenic factor for intestinal epithelial cells through the MAP kinase and NF-kappaB pathways. They also showed, for the first time, that leptin promotes colon cancer HT-29 cell survival upon butyrate challenge by counteracting the apoptotic programs initiated by this short chain fatty acid probably through the NF-kappaB pathways. Although further studies are required to unravel the precise mechanism, these data may have significance in the pathogenesis of colorectal cancer and ulcerative colitis diseases.
authors.affiliation: Laboratoire de Neuroendocrinologie et Biologie Cellular Digestives, INSERM U410, 75860 Paris Cedex 18, France.
authors.forename: Patricia
authors.initials: P
authors.lastname: Rouet-Benzineb
authors.forename: Thomas
authors.initials: T
authors.lastname: Aparicio
authors.forename: Sandra
authors.initials: S
authors.lastname: Guilmeau
authors.forename: Cécile
authors.initials: C
authors.lastname: Pouzet
authors.forename: Véronique
authors.initials: V
authors.lastname: Descatoire
authors.forename: Marion
authors.initials: M
authors.lastname: Buyse
authors.forename: André
authors.initials: A
authors.lastname: Bado
mesh_terms: D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D002087:Butyrates / Q000494:pharmacology; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000378:metabolism* / Q000473:pathology; D004336:Drug Antagonism; D006801:Humans; D020738:Leptin / Q000378:metabolism* / Q000494:pharmacology; D016328:NF-kappa B / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology
chemical_list: D002087:Butyrates; D020738:Leptin; D016328:NF-kappa B